Liquidia Corp current report, 14 July 2023

Full document

Liquidia Corporation Form 8-K Summary

Business Context and Reporting Period

Liquidia Corporation filed a Current Report on Form 8-K regarding a material definitive agreement entered into on July 14, 2023. Through its wholly owned subsidiary, Liquidia Technologies, Inc., the company amended and restated its commercial manufacturing and supply agreement with Lonza Tampa LLC, formerly Xcelience LLC.

Lonza is the company’s sole supplier for encapsulation and packaging services for YUTREPIATM (treprostinil) inhalation powder. Liquidia will supply bulk treprostinil powder manufactured using its proprietary PRINT® technology, while Lonza will provide encapsulation, packaging, and storage services.

Key Financial and Operating Terms

  • The agreement has an initial five-year term beginning upon FDA regulatory approval of YUTREPIA.
  • Liquidia must provide quarterly forecasts covering expected product requirements for a 24-month period. The nearest 12 months are firm orders; the remaining forecast period is non-binding.
  • Liquidia is subject to minimum annual purchase commitments, which may be adjusted after the thirteenth month following regulatory approval.
  • Lonza’s annual minimum capacity guarantees and Liquidia’s minimum annual commitments were materially increased compared with the prior agreement.
  • If the agreement is terminated following FDA rejection or FDA delay, Liquidia must reimburse Lonza for 50% of documented out-of-pocket expenditures for qualifying capital equipment purchased after the amended agreement’s effective date, subject to an aggregate cap of $2.5 million.
  • The filing does not provide revenue, earnings, cash flow, margin, debt, liquidity, or other periodic financial metrics.

Material Changes, Outlook, and Risks

  • The amended agreement replaces the November 12, 2022 commercial manufacturing services and supply agreement in its entirety.
  • Liquidia may terminate on 60 days’ notice if FDA approval is rejected for reasons not caused by Liquidia, or if approval is withdrawn or subject to a final non-appealable withdrawal order.
  • Lonza may terminate on 120 days’ notice if the FDA has not issued an approval letter by December 31, 2024.
  • The agreement creates increased supply capacity and purchase obligations before or in connection with regulatory approval and commercialization of YUTREPIA.
  • Key risks include FDA approval or timing delays, potential termination, minimum purchase commitments, reliance on Lonza as the sole encapsulation and packaging supplier, and potential reimbursement obligations of up to $2.5 million.
  • The filing states that customary representations, warranties, covenants, and indemnification provisions apply. The complete agreement was to be filed as an exhibit to the company’s next Form 10-Q.

Important Facts for Investors to Verify

  • FDA approval status and timing for YUTREPIA, including whether approval occurred by December 31, 2024.
  • The actual minimum annual purchase commitments and Lonza capacity guarantees in the complete agreement.
  • Any capital equipment expenditures or reimbursement obligations arising from termination.
  • Whether Liquidia continues to rely exclusively on Lonza for encapsulation and packaging and whether alternative suppliers are available.
  • Subsequent disclosures regarding commercialization plans, manufacturing costs, cash requirements, and liquidity.